suggested, systemic effects either by recirculation of immune cells through PD‐L1, B7‐H4, and VEGF‐positive tumor sites or by the release of biologically active soluble forms of PD‐L1, B7‐H4, and VEGF into the circulation cannot be excluded, indicating that both scenarios can contribute to global immunosuppression 26. The gene discussed is VTCN1; the disease is neoplasm.